3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
5
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
Paclitaxel
489
Carboplatin
435
Gemcitabine
394
Docetaxel
385
Cisplatin
359
pembrolizumab
343
Bevacizumab
335
Nivolumab
261
Pemetrexed
242
Capecitabine
221
Dexamethasone
213
Fluorouracil
211
Rituximab
203
Trastuzumab
193
Cyclophosphamide
190
Oxaliplatin
160
Erlotinib Hydrochloride
147
Ipilimumab
145
atezolizumab
144
Prednisone
144
Cetuximab
142
Irinotecan
139
Leucovorin
130
Doxorubicin
130
Sorafenib
120
Lenalidomide
119
Bortezomib
118
Sunitinib
107
Everolimus
93
130-nm albumin-bound paclitaxel
91
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
melflufen
×
Clear all
NCT02963493
2022-11-22
HORIZON
Oncopeptides AB
Phase 2
Completed
157 enrolled
26 charts
1 FDA